instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the outcome of reaction 'Dehydration'? | Successful Treatment of Symptomatic Epilepsy with Oral Valproic Acid and Levetiracetam in a Patient with Short-bowel Syndrome: A Case Report.
Valproic acid (VPA) and levetiracetam (LEV) are used in epilepsy treatment. However, their use to treat short-bowel syndrome has not been reported. We herein report a 68-year-old... | Recovered | ReactionOutcome | CC BY-NC-ND | 34670882 | 20,216,084 | 2021-10-19 |
What was the outcome of reaction 'Drug level increased'? | Successful Treatment of Symptomatic Epilepsy with Oral Valproic Acid and Levetiracetam in a Patient with Short-bowel Syndrome: A Case Report.
Valproic acid (VPA) and levetiracetam (LEV) are used in epilepsy treatment. However, their use to treat short-bowel syndrome has not been reported. We herein report a 68-year-old... | Recovering | ReactionOutcome | CC BY-NC-ND | 34670882 | 20,216,084 | 2021-10-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Alanine aminotransferase increased'. | A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radio... | METHOTREXATE, PROCARBAZINE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34670884 | 20,027,258 | 2021-10-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radio... | METHOTREXATE, PROCARBAZINE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34670884 | 20,027,258 | 2021-10-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hyponatraemia'. | A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radio... | METHOTREXATE, PROCARBAZINE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34670884 | 20,027,258 | 2021-10-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radio... | METHOTREXATE, PROCARBAZINE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34670884 | 20,027,258 | 2021-10-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Sepsis'. | A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radio... | METHOTREXATE, PROCARBAZINE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34670884 | 20,027,940 | 2021-10-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radio... | METHOTREXATE, PROCARBAZINE, RITUXIMAB, VINCRISTINE | DrugsGivenReaction | CC BY-NC-ND | 34670884 | 20,027,941 | 2021-10-19 |
What was the administration route of drug 'METHOTREXATE'? | A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radio... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34670884 | 20,027,258 | 2021-10-19 |
What was the administration route of drug 'RITUXIMAB'? | A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radio... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34670884 | 20,027,258 | 2021-10-19 |
What was the administration route of drug 'VINCRISTINE'? | A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radio... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 34670884 | 20,027,940 | 2021-10-19 |
What was the dosage of drug 'PROCARBAZINE'? | A Retrospective Analysis of R-MPV Plus Response-adapted Whole-brain Radiotherapy for Elderly Patients with Primary Central Nervous System Lymphoma.
Objective Few reports have described the real-world outcomes of rituximab, methotrexate (MTX), procarbazine, and vincristine (R-MPV) plus response-adapted whole-brain radio... | DURING ODD CYCLES | DrugDosageText | CC BY-NC-ND | 34670884 | 20,027,258 | 2021-10-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Dyspnoea'. | Pulmonary Tumor Thrombotic Microangiopathy Due to Gastric Cancer Diagnosed Antemortem by a Cytological Examination of Aspirated Pulmonary Artery Blood.
A 66-year-old Japanese man receiving systemic chemotherapy for advanced gastric cancer presented with exertional dyspnea. D-dimer was elevated in the blood. Echocardiog... | GIMERACIL\OTERACIL\TEGAFUR, OXALIPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34670901 | 20,951,482 | 2021-10-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Respiratory disorder'. | Pulmonary Tumor Thrombotic Microangiopathy Due to Gastric Cancer Diagnosed Antemortem by a Cytological Examination of Aspirated Pulmonary Artery Blood.
A 66-year-old Japanese man receiving systemic chemotherapy for advanced gastric cancer presented with exertional dyspnea. D-dimer was elevated in the blood. Echocardiog... | GIMERACIL\OTERACIL\TEGAFUR, OXALIPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34670901 | 20,951,482 | 2021-10-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | Pulmonary Tumor Thrombotic Microangiopathy Due to Gastric Cancer Diagnosed Antemortem by a Cytological Examination of Aspirated Pulmonary Artery Blood.
A 66-year-old Japanese man receiving systemic chemotherapy for advanced gastric cancer presented with exertional dyspnea. D-dimer was elevated in the blood. Echocardiog... | GIMERACIL\OTERACIL\TEGAFUR, OXALIPLATIN | DrugsGivenReaction | CC BY-NC-ND | 34670901 | 20,951,482 | 2021-10-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastatic salivary gland cancer'. | Salivary Duct Carcinoma: Case Reports and Brief Review of the Literature.
Salivary duct carcinoma (SDC) is an uncommon and highly aggressive tumor associated with high morbidity and mortality. According to the World Health Organization, it is an extremely rare malignancy with an estimated incidence of 1-1.2 in 1,000,00... | LAPATINIB, LEUPROLIDE ACETATE | DrugsGivenReaction | CC BY | 34671494 | 20,092,065 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Salivary Duct Carcinoma: Case Reports and Brief Review of the Literature.
Salivary duct carcinoma (SDC) is an uncommon and highly aggressive tumor associated with high morbidity and mortality. According to the World Health Organization, it is an extremely rare malignancy with an estimated incidence of 1-1.2 in 1,000,00... | LAPATINIB, LEUPROLIDE ACETATE | DrugsGivenReaction | CC BY | 34671494 | 20,092,065 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect variable'. | Salivary Duct Carcinoma: Case Reports and Brief Review of the Literature.
Salivary duct carcinoma (SDC) is an uncommon and highly aggressive tumor associated with high morbidity and mortality. According to the World Health Organization, it is an extremely rare malignancy with an estimated incidence of 1-1.2 in 1,000,00... | LAPATINIB, LEUPROLIDE ACETATE | DrugsGivenReaction | CC BY | 34671494 | 20,092,065 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Suicidality and Self-Harming Behaviors in Patients with Prader-Willi Syndrome (PWS): Case Report and Literature Review.
Prader-Willi syndrome (PWS) is a rare neurodevelopmental disorder which is often associated with significant behavioral challenges and poor intellectual functioning. Research has shown that individual... | FLUOXETINE HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34671495 | 20,171,666 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune-mediated renal disorder'. | Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report.
Immune checkpoints inhibitors (ICPIs), as either a frontline or adjuvant therapy, showed favorable outcomes among diverse malignancies. Immune-related adverse events (IRAEs) are increasingly encountered, but the kidneys are rarely affected. A... | DENOSUMAB, PEMBROLIZUMAB, SODIUM CHLORIDE | DrugsGivenReaction | CC BY | 34671624 | 20,017,682 | 2021 |
What was the administration route of drug 'DENOSUMAB'? | Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report.
Immune checkpoints inhibitors (ICPIs), as either a frontline or adjuvant therapy, showed favorable outcomes among diverse malignancies. Immune-related adverse events (IRAEs) are increasingly encountered, but the kidneys are rarely affected. A... | Subcutaneous | DrugAdministrationRoute | CC BY | 34671624 | 20,017,682 | 2021 |
What was the administration route of drug 'SODIUM CHLORIDE'? | Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report.
Immune checkpoints inhibitors (ICPIs), as either a frontline or adjuvant therapy, showed favorable outcomes among diverse malignancies. Immune-related adverse events (IRAEs) are increasingly encountered, but the kidneys are rarely affected. A... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34671624 | 20,017,682 | 2021 |
What was the dosage of drug 'DENOSUMAB'? | Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report.
Immune checkpoints inhibitors (ICPIs), as either a frontline or adjuvant therapy, showed favorable outcomes among diverse malignancies. Immune-related adverse events (IRAEs) are increasingly encountered, but the kidneys are rarely affected. A... | 60 MILLIGRAM | DrugDosageText | CC BY | 34671624 | 20,017,682 | 2021 |
What was the dosage of drug 'PEMBROLIZUMAB'? | Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report.
Immune checkpoints inhibitors (ICPIs), as either a frontline or adjuvant therapy, showed favorable outcomes among diverse malignancies. Immune-related adverse events (IRAEs) are increasingly encountered, but the kidneys are rarely affected. A... | 2 MILLIGRAM/KILOGRAM | DrugDosageText | CC BY | 34671624 | 20,017,682 | 2021 |
What was the outcome of reaction 'Immune-mediated renal disorder'? | Acute Diffuse Renal Tubulopathy in a Patient With Lung Cancer: A Case Report.
Immune checkpoints inhibitors (ICPIs), as either a frontline or adjuvant therapy, showed favorable outcomes among diverse malignancies. Immune-related adverse events (IRAEs) are increasingly encountered, but the kidneys are rarely affected. A... | Recovered | ReactionOutcome | CC BY | 34671624 | 20,017,682 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute kidney injury'. | Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitted to hospital with CO... | COLCHICINE | DrugsGivenReaction | CC BY | 34672950 | 20,204,786 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rhabdomyolysis'. | Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitted to hospital with CO... | COLCHICINE | DrugsGivenReaction | CC BY | 34672950 | 20,544,639 | 2021-12 |
What was the administration route of drug 'COLCHICINE'? | Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Colchicine has been proposed as a treatment for COVID-19 based on its anti-inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients admitted to hospital with CO... | Oral | DrugAdministrationRoute | CC BY | 34672950 | 20,204,786 | 2021-12 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19 pneumonia'. | COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab.
BACKGROUND
In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in thi... | RAVULIZUMAB-CWVZ | DrugsGivenReaction | CC BY | 34674707 | 20,025,525 | 2021-10-21 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'SARS-CoV-2 test positive'. | COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab.
BACKGROUND
In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in thi... | RAVULIZUMAB-CWVZ | DrugsGivenReaction | CC BY | 34674707 | 20,025,525 | 2021-10-21 |
What was the administration route of drug 'RAVULIZUMAB-CWVZ'? | COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab.
BACKGROUND
In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in thi... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34674707 | 20,025,525 | 2021-10-21 |
What was the outcome of reaction 'COVID-19 pneumonia'? | COVID19 infection in a patient undergoing treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH) with Ravulizumab.
BACKGROUND
In the recent COVID19 pandemic, patients with hematological disorders were considered at high risk for severe disease. Limited data is available regarding the course of COVID19 infection in thi... | Recovered | ReactionOutcome | CC BY | 34674707 | 20,025,525 | 2021-10-21 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports.
BACKGROUND
Diabetic papillopathy is a rare diagnosis of exclusion characterized by unilateral or bilateral optic disc edema with variable degrees of visual loss. Although the visual p... | AFLIBERCEPT, INSULIN NOS, TRIAMCINOLONE ACETONIDE | DrugsGivenReaction | CC BY | 34674724 | 20,020,241 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Ocular hypertension'. | Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports.
BACKGROUND
Diabetic papillopathy is a rare diagnosis of exclusion characterized by unilateral or bilateral optic disc edema with variable degrees of visual loss. Although the visual p... | AFLIBERCEPT, INSULIN NOS, TRIAMCINOLONE ACETONIDE | DrugsGivenReaction | CC BY | 34674724 | 20,145,752 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports.
BACKGROUND
Diabetic papillopathy is a rare diagnosis of exclusion characterized by unilateral or bilateral optic disc edema with variable degrees of visual loss. Although the visual p... | AFLIBERCEPT, INSULIN NOS, TRIAMCINOLONE ACETONIDE | DrugsGivenReaction | CC BY | 34674724 | 20,145,752 | 2021-10-22 |
What was the administration route of drug 'AFLIBERCEPT'? | Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports.
BACKGROUND
Diabetic papillopathy is a rare diagnosis of exclusion characterized by unilateral or bilateral optic disc edema with variable degrees of visual loss. Although the visual p... | Intraocular | DrugAdministrationRoute | CC BY | 34674724 | 20,020,241 | 2021-10-22 |
What was the dosage of drug 'AFLIBERCEPT'? | Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports.
BACKGROUND
Diabetic papillopathy is a rare diagnosis of exclusion characterized by unilateral or bilateral optic disc edema with variable degrees of visual loss. Although the visual p... | INTRAVITREAL INJECTION | DrugDosageText | CC BY | 34674724 | 20,020,241 | 2021-10-22 |
What was the dosage of drug 'TRIAMCINOLONE ACETONIDE'? | Combined therapy with intravitreal aflibercept and subtenon corticosteroids in eyes with severe diabetic papillopathy: two case reports.
BACKGROUND
Diabetic papillopathy is a rare diagnosis of exclusion characterized by unilateral or bilateral optic disc edema with variable degrees of visual loss. Although the visual p... | SUBTENON TRIAMCINOLONE ACETONIDE INJECTION | DrugDosageText | CC BY | 34674724 | 20,020,241 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nocardiosis'. | Membranous Nephropathy Complicated with Disseminated Nocardia farcinica Infection: A Case Report and Literature Review.
Disseminated infection caused by Nocardia farcinica with primary nephrotic syndrome is exceedingly rare. A 66-year-old female visited the outpatient department due to fever and fatigue who had been di... | CYCLOPHOSPHAMIDE, PREDNISONE, TACROLIMUS | DrugsGivenReaction | CC BY-NC | 34675560 | 20,047,806 | 2021 |
What was the administration route of drug 'TACROLIMUS'? | Membranous Nephropathy Complicated with Disseminated Nocardia farcinica Infection: A Case Report and Literature Review.
Disseminated infection caused by Nocardia farcinica with primary nephrotic syndrome is exceedingly rare. A 66-year-old female visited the outpatient department due to fever and fatigue who had been di... | Oral | DrugAdministrationRoute | CC BY-NC | 34675560 | 20,047,806 | 2021 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | Membranous Nephropathy Complicated with Disseminated Nocardia farcinica Infection: A Case Report and Literature Review.
Disseminated infection caused by Nocardia farcinica with primary nephrotic syndrome is exceedingly rare. A 66-year-old female visited the outpatient department due to fever and fatigue who had been di... | 1 g (grams). | DrugDosage | CC BY-NC | 34675560 | 20,047,806 | 2021 |
What was the dosage of drug 'TACROLIMUS'? | Membranous Nephropathy Complicated with Disseminated Nocardia farcinica Infection: A Case Report and Literature Review.
Disseminated infection caused by Nocardia farcinica with primary nephrotic syndrome is exceedingly rare. A 66-year-old female visited the outpatient department due to fever and fatigue who had been di... | 1 mg (milligrams). | DrugDosage | CC BY-NC | 34675560 | 20,047,806 | 2021 |
What was the outcome of reaction 'Nocardiosis'? | Membranous Nephropathy Complicated with Disseminated Nocardia farcinica Infection: A Case Report and Literature Review.
Disseminated infection caused by Nocardia farcinica with primary nephrotic syndrome is exceedingly rare. A 66-year-old female visited the outpatient department due to fever and fatigue who had been di... | Recovering | ReactionOutcome | CC BY-NC | 34675560 | 20,047,806 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Substance-induced psychotic disorder'. | Steroid-induced psychosis in a child with croup: A case report.
Corticosteroids are effective for the treatment of many chronic and acute diseases but have many well-known adverse effects, which limit their use in some conditions. Steroid-induced psychosis is a rare side effect especially in the pediatric population. A... | DEXAMETHASONE | DrugsGivenReaction | CC BY-NC | 34676078 | 20,032,152 | 2021 |
What is the weight of the patient? | Steroid-induced psychosis in a child with croup: A case report.
Corticosteroids are effective for the treatment of many chronic and acute diseases but have many well-known adverse effects, which limit their use in some conditions. Steroid-induced psychosis is a rare side effect especially in the pediatric population. A... | 14 kg. | Weight | CC BY-NC | 34676078 | 20,032,152 | 2021 |
What was the administration route of drug 'DEXAMETHASONE'? | Steroid-induced psychosis in a child with croup: A case report.
Corticosteroids are effective for the treatment of many chronic and acute diseases but have many well-known adverse effects, which limit their use in some conditions. Steroid-induced psychosis is a rare side effect especially in the pediatric population. A... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34676078 | 20,032,152 | 2021 |
What was the outcome of reaction 'Substance-induced psychotic disorder'? | Steroid-induced psychosis in a child with croup: A case report.
Corticosteroids are effective for the treatment of many chronic and acute diseases but have many well-known adverse effects, which limit their use in some conditions. Steroid-induced psychosis is a rare side effect especially in the pediatric population. A... | Recovered | ReactionOutcome | CC BY-NC | 34676078 | 20,032,152 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Acute psychosis'. | COVID-19 Induced New-onset Psychosis: A Case Report from Oman.
Neurobehavioral impairment associated with COVID-19 infection has been recently documented in the literature. COVID-19 infection has also been associated with an increased risk for developing psychiatric symptoms, including rare reports on psychosis. We rep... | AZITHROMYCIN, CEFTRIAXONE, DEXAMETHASONE, HYDROXYCHLOROQUINE, OLANZAPINE | DrugsGivenReaction | CC BY-NC | 34676111 | 20,313,030 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Discomfort'. | COVID-19 Induced New-onset Psychosis: A Case Report from Oman.
Neurobehavioral impairment associated with COVID-19 infection has been recently documented in the literature. COVID-19 infection has also been associated with an increased risk for developing psychiatric symptoms, including rare reports on psychosis. We rep... | AZITHROMYCIN, CEFTRIAXONE, DEXAMETHASONE, HYDROXYCHLOROQUINE, OLANZAPINE | DrugsGivenReaction | CC BY-NC | 34676111 | 20,313,030 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Laziness'. | COVID-19 Induced New-onset Psychosis: A Case Report from Oman.
Neurobehavioral impairment associated with COVID-19 infection has been recently documented in the literature. COVID-19 infection has also been associated with an increased risk for developing psychiatric symptoms, including rare reports on psychosis. We rep... | AZITHROMYCIN, CEFTRIAXONE, DEXAMETHASONE, HYDROXYCHLOROQUINE, OLANZAPINE | DrugsGivenReaction | CC BY-NC | 34676111 | 20,313,030 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | COVID-19 Induced New-onset Psychosis: A Case Report from Oman.
Neurobehavioral impairment associated with COVID-19 infection has been recently documented in the literature. COVID-19 infection has also been associated with an increased risk for developing psychiatric symptoms, including rare reports on psychosis. We rep... | AZITHROMYCIN, CEFTRIAXONE, DEXAMETHASONE, HYDROXYCHLOROQUINE, OLANZAPINE | DrugsGivenReaction | CC BY-NC | 34676111 | 20,313,030 | 2021-09 |
What was the administration route of drug 'AZITHROMYCIN'? | COVID-19 Induced New-onset Psychosis: A Case Report from Oman.
Neurobehavioral impairment associated with COVID-19 infection has been recently documented in the literature. COVID-19 infection has also been associated with an increased risk for developing psychiatric symptoms, including rare reports on psychosis. We rep... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34676111 | 20,313,030 | 2021-09 |
What was the administration route of drug 'CEFTRIAXONE'? | COVID-19 Induced New-onset Psychosis: A Case Report from Oman.
Neurobehavioral impairment associated with COVID-19 infection has been recently documented in the literature. COVID-19 infection has also been associated with an increased risk for developing psychiatric symptoms, including rare reports on psychosis. We rep... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC | 34676111 | 20,313,030 | 2021-09 |
What was the administration route of drug 'OLANZAPINE'? | COVID-19 Induced New-onset Psychosis: A Case Report from Oman.
Neurobehavioral impairment associated with COVID-19 infection has been recently documented in the literature. COVID-19 infection has also been associated with an increased risk for developing psychiatric symptoms, including rare reports on psychosis. We rep... | Oral | DrugAdministrationRoute | CC BY-NC | 34676111 | 20,313,030 | 2021-09 |
What was the outcome of reaction 'Acute psychosis'? | COVID-19 Induced New-onset Psychosis: A Case Report from Oman.
Neurobehavioral impairment associated with COVID-19 infection has been recently documented in the literature. COVID-19 infection has also been associated with an increased risk for developing psychiatric symptoms, including rare reports on psychosis. We rep... | Recovered | ReactionOutcome | CC BY-NC | 34676111 | 20,313,030 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Alopecia'. | Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.
Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcit... | CISPLATIN, GEMCITABINE HYDROCHLORIDE, PACLITAXEL | DrugsGivenReaction | CC BY | 34676166 | 20,048,847 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Leukopenia'. | Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.
Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcit... | CISPLATIN, GEMCITABINE HYDROCHLORIDE, PACLITAXEL | DrugsGivenReaction | CC BY | 34676166 | 20,048,847 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mouth ulceration'. | Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.
Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcit... | CISPLATIN, GEMCITABINE HYDROCHLORIDE, PACLITAXEL | DrugsGivenReaction | CC BY | 34676166 | 20,048,847 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapy partial responder'. | Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.
Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcit... | CISPLATIN, GEMCITABINE, PACLITAXEL, PROPRANOLOL HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34676166 | 20,144,090 | 2021 |
What was the dosage of drug 'CISPLATIN'? | Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.
Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcit... | UNK/TWO CYCLES | DrugDosageText | CC BY | 34676166 | 20,144,090 | 2021 |
What was the dosage of drug 'GEMCITABINE'? | Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.
Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcit... | UNK/TWO CYCLES | DrugDosageText | CC BY | 34676166 | 20,144,090 | 2021 |
What was the dosage of drug 'PACLITAXEL'? | Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.
Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcit... | UNK/ TWO CYCLES | DrugDosageText | CC BY | 34676166 | 20,144,090 | 2021 |
What was the outcome of reaction 'Leukopenia'? | Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.
Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcit... | Recovered | ReactionOutcome | CC BY | 34676166 | 20,048,847 | 2021 |
What was the outcome of reaction 'Mouth ulceration'? | Long-Term Response to Gemcitabine, Cisplatin, and Nab-Paclitaxel Followed by Maintenance Therapy for Advanced Gallbladder Cancer: A Case Report and Literature Review.
Gallbladder cancer (GBC) is the most common and devastating tumor type of biliary tract cancer (BTC) with poor outcomes. A new combined regimen of gemcit... | Recovered | ReactionOutcome | CC BY | 34676166 | 20,048,847 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Histological regression of gastrointestinal peritoneal metastases after systemic chemotherapy.
Peritoneal metastases (PM) are relatively resistant to systemic chemotherapy, and data on histological response to therapy is rare. The aim of this study was to quantify the treatment response of PM after systemic chemotherap... | PANITUMUMAB | DrugsGivenReaction | CC BY | 34676284 | 20,483,637 | 2021-09 |
What was the outcome of reaction 'Death'? | Histological regression of gastrointestinal peritoneal metastases after systemic chemotherapy.
Peritoneal metastases (PM) are relatively resistant to systemic chemotherapy, and data on histological response to therapy is rare. The aim of this study was to quantify the treatment response of PM after systemic chemotherap... | Fatal | ReactionOutcome | CC BY | 34676284 | 20,483,637 | 2021-09 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Intentional overdose'. | Internet Search Activity of Young People With Mood Disorders Who Are Hospitalized for Suicidal Thoughts and Behaviors: Qualitative Study of Google Search Activity.
BACKGROUND
Little is known about the internet search activity of people with suicidal thoughts and behaviors (STBs). This data source has the potential to i... | ACETAMINOPHEN\DEXTROMETHORPHAN HYDROBROMIDE\DOXYLAMINE SUCCINATE\PHENYLEPHRINE HYDROCHLORIDE | DrugsGivenReaction | CC BY | 34677139 | 20,543,449 | 2021-10-22 |
What was the administration route of drug 'ACETAMINOPHEN\DEXTROMETHORPHAN HYDROBROMIDE\DOXYLAMINE SUCCINATE\PHENYLEPHRINE HYDROCHLORIDE'? | Internet Search Activity of Young People With Mood Disorders Who Are Hospitalized for Suicidal Thoughts and Behaviors: Qualitative Study of Google Search Activity.
BACKGROUND
Little is known about the internet search activity of people with suicidal thoughts and behaviors (STBs). This data source has the potential to i... | Oral | DrugAdministrationRoute | CC BY | 34677139 | 20,543,449 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Decreased appetite'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Epistaxis'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hypertension'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oedema'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Palmar-plantar erythrodysaesthesia syndrome'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Proteinuria'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pruritus'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rash'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Stomatitis'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thyroid function test abnormal'. | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
What was the administration route of drug 'ATEZOLIZUMAB'? | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
What was the administration route of drug 'BEVACIZUMAB'? | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
What was the dosage of drug 'ATEZOLIZUMAB'? | Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma.
Combination therapy with anti-programmed death-ligand 1 monoclonal antibody atezolizumab plus anti-vascular endothelial growth factor agent bevacizumab (Atezo/Bev) was approved i... | 1200 mg (milligrams). | DrugDosage | CC BY | 34677270 | 20,039,340 | 2021-10-14 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Radiological and clinical findings of idiopathic myointimal hyperplasia of mesenteric veins: Case report.
BACKGROUND
Idiopathic myointimal hyperplasia of mesenteric veins (IMHMV) is an uncommon cause of ischemic bowel disease resulting from the proliferation of smooth muscles in the venous intima. Delayed diagnosis cou... | MESALAMINE, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY | 34678900 | 20,056,506 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haematochezia'. | Radiological and clinical findings of idiopathic myointimal hyperplasia of mesenteric veins: Case report.
BACKGROUND
Idiopathic myointimal hyperplasia of mesenteric veins (IMHMV) is an uncommon cause of ischemic bowel disease resulting from the proliferation of smooth muscles in the venous intima. Delayed diagnosis cou... | MESALAMINE, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY | 34678900 | 20,056,506 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haemoglobin decreased'. | Radiological and clinical findings of idiopathic myointimal hyperplasia of mesenteric veins: Case report.
BACKGROUND
Idiopathic myointimal hyperplasia of mesenteric veins (IMHMV) is an uncommon cause of ischemic bowel disease resulting from the proliferation of smooth muscles in the venous intima. Delayed diagnosis cou... | MESALAMINE, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY | 34678900 | 20,056,506 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Product use in unapproved indication'. | Radiological and clinical findings of idiopathic myointimal hyperplasia of mesenteric veins: Case report.
BACKGROUND
Idiopathic myointimal hyperplasia of mesenteric veins (IMHMV) is an uncommon cause of ischemic bowel disease resulting from the proliferation of smooth muscles in the venous intima. Delayed diagnosis cou... | MESALAMINE, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY | 34678900 | 20,056,506 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Shock'. | Radiological and clinical findings of idiopathic myointimal hyperplasia of mesenteric veins: Case report.
BACKGROUND
Idiopathic myointimal hyperplasia of mesenteric veins (IMHMV) is an uncommon cause of ischemic bowel disease resulting from the proliferation of smooth muscles in the venous intima. Delayed diagnosis cou... | MESALAMINE, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY | 34678900 | 20,056,506 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'White blood cell count increased'. | Radiological and clinical findings of idiopathic myointimal hyperplasia of mesenteric veins: Case report.
BACKGROUND
Idiopathic myointimal hyperplasia of mesenteric veins (IMHMV) is an uncommon cause of ischemic bowel disease resulting from the proliferation of smooth muscles in the venous intima. Delayed diagnosis cou... | MESALAMINE, METHYLPREDNISOLONE | DrugsGivenReaction | CC BY | 34678900 | 20,056,506 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Disease progression'. | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic function abnormal'. | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Immune system disorder'. | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastases to adrenals'. | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Tumour lysis syndrome'. | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | ATEZOLIZUMAB, BEVACIZUMAB | DrugsGivenReaction | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
What was the administration route of drug 'ATEZOLIZUMAB'? | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | Intravenous drip | DrugAdministrationRoute | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
What was the administration route of drug 'BEVACIZUMAB'? | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | Intravenous drip | DrugAdministrationRoute | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
What was the outcome of reaction 'Disease progression'? | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | Recovered | ReactionOutcome | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
What was the outcome of reaction 'Hepatic function abnormal'? | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | Recovered | ReactionOutcome | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
What was the outcome of reaction 'Immune system disorder'? | Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
BACKGROUND
Various treatments are available for treating hepatocellular carcinoma (HCC). The immune checkpoint inhibitor combination of atezolizumab plus bevacizumab was recently approved for the treatment of unresectable... | Recovered | ReactionOutcome | CC BY | 34678902 | 18,435,387 | 2021-10-22 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.